What is PsiThera?
PsiThera operates at the intersection of biotechnology and computational intelligence, focusing on the development of oral drugs for complex immune and inflammatory conditions. The company distinguishes itself by mapping biologically relevant protein states, a process that allows its team of drug hunters to identify and optimize therapeutic candidates with unprecedented precision. Its current pipeline is anchored by a strategic focus on the Tumor Necrosis Factor (TNF) superfamily, a high-value target area that has historically presented significant challenges for traditional pharmaceutical development.
By integrating computational modeling with deep mechanistic biology, PsiThera is effectively shortening the discovery cycle. This approach not only enhances the probability of success for its lead candidates but also positions the company as a disruptive force in the biopharmaceutical sector, capable of addressing unmet medical needs that have long remained resistant to conventional therapeutic modalities.
How much funding has PsiThera raised?
PsiThera has raised a total of $47.5M across 1 funding round:
Series A
$47.5M
Series A (2025): $47.5M with participation from Lightstone Ventures, Samsara BioCapital, Eurofarma, and Roivant Sciences
Key Investors in PsiThera
Lightstone Ventures
Lightstone Ventures backs founders turning cutting edge science into new therapies and medical technologies. Its team partners closely with biotech and medtech leaders, providing capital, insight and connections to help transform promising lab ideas into treatments for patients.
Samsara BioCapital
Samsara BioCapital is focused on investing to create transformative therapeutics for patients. The company partners with scientists, physicians, drug developers, and business leaders to support the next generation of therapeutic breakthroughs.
Roivant Sciences
Roivant Sciences is a tech-enabled healthcare company focused on completing the development of promising late-stage drug candidates and delivering innovative healthcare technologies to patients.
What's next for PsiThera?
With the recent influx of capital, PsiThera is poised to scale its research and development operations significantly. The strategic roadmap involves advancing its lead candidates through the preclinical pipeline while further refining its computational intelligence engine to identify additional high-value targets. As the company matures, the focus will likely shift toward establishing clinical proof-of-concept, a critical phase that will validate the efficacy of its oral drug delivery platform in human subjects.
Furthermore, the company is expected to leverage its strong investor syndicate to foster collaborative partnerships that could expedite regulatory pathways and commercialization efforts. By maintaining a rigorous focus on scientific excellence and operational efficiency, PsiThera is well-equipped to navigate the complexities of the drug development lifecycle, ultimately aiming to transform the standard of care for patients with immune-mediated diseases.
